{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:34:40Z","timestamp":1792812880128,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00939-7","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T14:11:25Z","timestamp":1777299085000},"page":"1573-1591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment Characteristics and Healthcare Resource Utilization Among Patients with Myasthenia Gravis Initiating Rozanolixizumab: A US Claims Database Analysis"],"prefix":"10.1007","volume":"15","author":[{"given":"Mohita","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandria","family":"Harrold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaksa","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Bardenheuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tha\u00efs","family":"Taranc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo","family":"Pata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"939_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Prim. 2019,5:30.","journal-title":"Nat Rev Dis Prim"},{"key":"939_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015,14:1023\u201336.","journal-title":"Lancet Neurol"},{"key":"939_CR3","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3389\/fneur.2020.00660","volume":"11","author":"C Rodolico","year":"2020","unstructured":"Rodolico C, Bonanno C, Toscano A, Vita G. MuSK-associated myasthenia gravis: clinical features and management. Front Neurol. 2020,11:660.","journal-title":"Front Neurol"},{"key":"939_CR4","first-page":"1111","volume":"10","author":"B Smith","year":"2018","unstructured":"Smith B, et al. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. MAbs. 2018,10:1111\u201330.","journal-title":"MAbs"},{"key":"939_CR5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive Phase 3 study. Lancet Neurol. 2023,22:383\u201394.","journal-title":"Lancet Neurol"},{"key":"939_CR6","doi-asserted-by":"crossref","unstructured":"Sirina J, et al. The uptake, intracellular trafficking and recycling of FcRn-blocking therapeutics in human endothelial cells in vitro. mAbs. 2025, submitted.","DOI":"10.1016\/j.cellimm.2026.105128"},{"key":"939_CR7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/22143602241305511","volume":"12","author":"V Bril","year":"2025","unstructured":"Bril V, et al. Rozanolixizumab in generalized myasthenia gravis: pooled analysis of the Phase 3 MycarinG study and two open-label extensions. J Neuromuscul Dis. 2025,12:218\u201330.","journal-title":"J Neuromuscul Dis"},{"key":"939_CR8","unstructured":"Habib AA, et al. Efficacy and safety of rozanolixizumab treatment cycles in patients with generalised myasthenia gravis: final pooled analysis of Phase 3 studies. MGFA International 2025. Poster 71."},{"key":"939_CR9","unstructured":"Rystiggo US PI. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761286s000lbl.pdf. Accessed June 2025."},{"key":"939_CR10","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s40265-023-01933-1","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM. Rozanolixizumab: first approval. Drugs. 2023,83:1341\u20137.","journal-title":"Drugs"},{"key":"939_CR11","unstructured":"Komodo Health. Why choose Komodo Health. https:\/\/www.komodohealth.com\/why-komodo. Accessed Sept 2025."},{"key":"939_CR12","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0108","volume":"13","author":"J Pisc","year":"2024","unstructured":"Pisc J, Ting A, Skornicki M, Sinno O, Lee E. Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the US: a retrospective analysis of claims data. J Comp Eff Res. 2024,13:e230108.","journal-title":"J Comp Eff Res"},{"key":"939_CR13","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s40120-025-00714-0","volume":"14","author":"M Pujades-Rodr\u00edguez","year":"2025","unstructured":"Pujades-Rodr\u00edguez M, Jedrzejczyk A, Zhou J, Pilipczuk O, Taranc\u00f3n T. High-dose steroids, treatment escalation, and healthcare burden in myasthenia gravis: a US claims-based cohort study. Neurol Ther. 2025,14:1061\u201382.","journal-title":"Neurol Ther"},{"key":"939_CR14","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1212\/WNL.0000000000203563","volume":"100","author":"Y Hua","year":"2023","unstructured":"Hua Y, Semenov Y, Guidon A. Application of a validated algorithm to identify and describe contemporary epidemiology of privately insured myasthenia gravis patients in the United States. Neurology. 2023,100:3840.","journal-title":"Neurology"},{"key":"939_CR15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213736","volume":"105","author":"J Zhou","year":"2025","unstructured":"Zhou J, et al. Treatment patterns and disease burden of juvenile myasthenia gravis in the United States: a cohort study using health care claims databases. Neurology. 2025,105:e213736.","journal-title":"Neurology"},{"key":"939_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA. Efgartigimod: first approval. Drugs. 2022,82:341\u20138.","journal-title":"Drugs"},{"key":"939_CR17","unstructured":"VYVGART\u00ae\u00a0US PI. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761304s000lbl.pdf. Accessed Sept 2025."},{"key":"939_CR18","unstructured":"argenx. argenx announces FDA approval of VYVGART Hytrulo prefilled syringe for self-injection in generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. https:\/\/argenx.com\/content\/dam\/argenx-corp\/media-documents\/argenx_PFS%20Approval%20PDUFA%20Release_FINAL.pdf.coredownload.inline.pdf. Accessed Sept 2025."},{"key":"939_CR19","unstructured":"RYSTIGGO\u00ae US PI. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761286s000lbl.pdf. Accessed Sept 2025."},{"key":"939_CR20","doi-asserted-by":"publisher","first-page":"175628642312132","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, et al. Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord. 2023,16:17562864231213240.","journal-title":"Ther Adv Neurol Disord"},{"key":"939_CR21","doi-asserted-by":"publisher","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","volume":"94","author":"E Cort\u00e9s-Vicente","year":"2020","unstructured":"Cort\u00e9s-Vicente E, et al. Clinical and therapeutic features of myasthenia gravis in adults based on age at onset. Neurology. 2020,94:e1171\u201380.","journal-title":"Neurology"},{"key":"939_CR22","unstructured":"Vu T, et al. Rozanolixizumab in patients aged \u226565 years with generalized myasthenia gravis: a post hoc analysis of the Phase 3 MycarinG study [poster]. AANEM 2024. Poster 300."},{"key":"939_CR23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ana.26169","volume":"90","author":"L Handunnetthi","year":"2021","unstructured":"Handunnetthi L, et al. Genomic insights into myasthenia gravis identify distinct immunological mechanisms in early and late onset disease. Ann Neurol. 2021,90:455\u201363.","journal-title":"Ann Neurol"},{"key":"939_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s42466-020-00091-z","volume":"2","author":"F Pasqualin","year":"2020","unstructured":"Pasqualin F, Guidoni SV, Ermani M, Pegoraro E, Bonifati DM. Outcome measures and treatment effectiveness in late onset myasthenia gravis. Neurol Res Pract. 2020,2:45.","journal-title":"Neurol Res Pract"},{"key":"939_CR25","doi-asserted-by":"publisher","first-page":"1641701","DOI":"10.3389\/fneur.2025.1641701","volume":"16","author":"I Liampas","year":"2025","unstructured":"Liampas I, Veltsista D, Batzikosta P, Lazarou L, Kefalopoulou ZM, Chroni E. The short-term prognosis of very late onset generalized myasthenia gravis: a single-center retrospective cohort study. Front Neurol. 2025,16:1641701.","journal-title":"Front Neurol"},{"key":"939_CR26","unstructured":"Studies highlight risks of excluding people with obesity from drug trials. https:\/\/www.statnews.com\/2023\/10\/16\/obesity-drug-trials-representation\/. Accessed Oct 2025."},{"key":"939_CR27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/22143602241308181","volume":"12","author":"AA Habib","year":"2025","unstructured":"Habib AA, et al. Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: results from the Phase 3 MycarinG study and an open-label extension. J Neuromuscul Dis. 2025,12:231\u201343.","journal-title":"J Neuromuscul Dis"},{"key":"939_CR28","doi-asserted-by":"publisher","first-page":"1284444","DOI":"10.3389\/fneur.2023.1284444","volume":"14","author":"JF Howard","year":"2023","unstructured":"Howard JF, et al. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis. Front Neurol. 2023,14:1284444.","journal-title":"Front Neurol"},{"key":"939_CR29","unstructured":"ClinicalTrials.gov. NCT04951622. https:\/\/clinicaltrials.gov\/study\/NCT04951622. Accessed Nov 2025."},{"key":"939_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00415-025-13113-0","volume":"272","author":"C Hewamadduma","year":"2025","unstructured":"Hewamadduma C, et al. Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis. J Neurol. 2025,272:457.","journal-title":"J Neurol"},{"key":"939_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cen3.12739","volume":"14","author":"H Murai","year":"2023","unstructured":"Murai H, Utsugisawa K, Motomura M, Imai T, Uzawa A, Suzuki S. The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert-Eaton myasthenic syndrome. Clin Exp Neuroimmunol. 2023,14:19\u201327.","journal-title":"Clin Exp Neuroimmunol"},{"key":"939_CR32","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","volume":"39","author":"JB Rice","year":"2017","unstructured":"Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017,39:2216\u201329.","journal-title":"Clin Ther"},{"key":"939_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/ane.13549","volume":"145","author":"E Klimiec-Moskal","year":"2022","unstructured":"Klimiec-Moskal E, Quirke M, Leite MI. Comorbidities in older patients with myasthenia gravis\u2014comparison between early- and late-onset disease. Acta Neurol Scand. 2022,145:371\u20134.","journal-title":"Acta Neurol Scand"},{"key":"939_CR34","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1007\/s10072-024-07368-0","volume":"45","author":"V Di Stefano","year":"2024","unstructured":"Di Stefano V, et al. Comorbidity in myasthenia gravis: multicentric, hospital-based, and controlled study of 178 Italian patients. Neurol Sci. 2024,45:3481\u201394.","journal-title":"Neurol Sci"},{"key":"939_CR35","unstructured":"BNF NICE. Prednisolone. https:\/\/bnf.nice.org.uk\/drugs\/prednisolone\/. Accessed Jan 2025."},{"key":"939_CR36","unstructured":"Pascuzzi RM, et al. Corticosteroid dose tapering during treatment with rozanolixizumab in patients with generalized myasthenia gravis: Post hoc analysis [oral]. MGFA SS 2025."},{"key":"939_CR37","doi-asserted-by":"publisher","first-page":"175628642513320","DOI":"10.1177\/17562864251332037","volume":"18","author":"S Marini","year":"2025","unstructured":"Marini S, Falso S, Habetswallner F, Marini M, Iorio R. Complement inhibitor therapy as a steroid-sparing strategy in generalized myasthenia gravis. Ther Adv Neurol Disord. 2025,18:17562864251332037.","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00939-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00939-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:25Z","timestamp":1784819485000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00939-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["939"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00939-7","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Minjee Park and Aaksa Nair are employees of Alira Health. Angela Ting is a former employee and shareholder of UCB, and current employee of Sobi, North America. Kristina Bardenheuer, Alexandria Harrold and Mohita Kumar, Diogo Pata and Tha\u00efs Taranc\u00f3n are employees and shareholders of UCB.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The databases used in this study consist of de-identified data compliant with the US HIPAA of 1996, so\u00a0no ethics committee approval was required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}